Faegheh Nooriankafshgari

Dr. Faegheh Nooriankafshgari

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
FNFaegheh Nooriankafshgari
Faegheh Nooriankafshgari
RARosa Abellana
Rosa Abellana
YZYaowen Zhang
Yaowen Zhang
AMAntonio Herreros Martínez
Antonio Herreros Martínez
VLValentina Lancellotta
Valentina Lancellotta
Ángeles RovirosaÁngeles Rovirosa
Ángeles Rovirosa
Background: This study evaluated the clinical outcomes of applying a 68 Gy EQD2(α/β=3) dose constraint to the most exposed 2 cm3 area of the vagina in post-operative endometrial cancer patients treated with vaginal-cuff brachytherapy after external beam irradiation and the impact of vaginal dilator use on late vaginal complications. Material and methods: We analyzed 131 patients treated with vaginal-cuff brachytherapy after external beam irradiation. Group-1 (65 patients) received one fraction of 7 Gy, and Group-2 (66 patients) received one fraction of between 5.5 and 7.0 Gy after applying a 68 Gy EQD2(α/β=3) dose constraint. Vaginal-cuff relapse, late toxicity, clinical target volume, vaginal dilator use, D90, and EQD2(α/β=3) at 2 cm3 of the most exposed part of the clinical target volume were evaluated. Descriptive analysis, the chi-squared test, Student’s t-test, and the Cox proportional and Kaplan–Meier models were used for the statistical analysis. Results: With a median follow-up of 60 months, the vaginal-cuff relapse rate was 1/131 (0.8%). Late vaginal complications appeared in 36/65 (55.4%) Group-1 patients and 17/66 (25.8%) Group-2 patients (p = 0.003). Multivariate analysis showed that belonging to Group-1 and vaginal dilator use of <9 months were independent prognostic factors of late vaginal complications with hazard ratios of 1.99 (p = 0.021) and 3.07 (p = 0.010), respectively. Conclusions: A 68 Gy EQD2(α/β=3) constraint at 2 cm3 of clinical target volume and vaginal dilator use of ≥9 months were independent prognostic factors, having protective effects on late vaginal complications.

31 December 2025 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
ELElena Lluzar
Elena Lluzar
ACAdriana Capdevila
Adriana Capdevila
FNFaegheh Nooriankafshgari
Faegheh Nooriankafshgari
AMAntonio Herreros Martínez
Antonio Herreros Martínez
CCCristina Castro
Cristina Castro
Ángeles RovirosaÁngeles Rovirosa
Ángeles Rovirosa
Background: A subset of patients with T1-T2 oesophageal cancer are not candidates for surgery or chemotherapy and have a poor prognosis due to limited treatment options. This study evaluated the combination of external beam radiotherapy (EBRT) and endo-oesophageal brachytherapy (EBT) as a curative treatment in these patients, with cause-specific survival (CSS) and local recurrence-free survival (LRFS) as the primary endpoints. Methods: This was a single-centre retrospective analysis of 11 patients with T1-T2 oesophageal cancer treated between 2005 and 2024 with combined EBRT and EBT schedules. Clinical data, treatment schedules, outcomes, and complications were obtained from patient medical records and follow-up documentation. Descriptive statistics and Kaplan–Meier survival analysis were used. Results: The median follow-up was 22 months (2–61 months). CSS rates were 79.5% at 2 years, 66% at 3 years, and 30% at 5 years. LRFS rates were 74.1%, 59%, and 39%, respectively. One severe toxicity (grade ≥ 3) was observed. The most frequent mild toxicities were oesophageal mucositis (18.2%) and ulceration (18.2%). Conclusions: EBT in combination with EBRT seems to be a feasible and well-tolerated treatment with curative intent for inoperable T1-T2 oesophageal cancer patients, offering favourable survival outcomes in a population with limited therapeutic alternatives.

21 July 2026 in Cancers
Verified
Journal Article
Open access
PDF file
QYQiang Yao
Qiang Yao
FNFaegheh Nooriankafshgari
Faegheh Nooriankafshgari
RARosa Abellana
Rosa Abellana
CBClara Baltrons
Clara Baltrons
VLValentina Lancellotta
Valentina Lancellotta
Ángeles RovirosaÁngeles Rovirosa
Ángeles Rovirosa
Background/Objectives: To evaluate clinical and dosimetric predictors of vaginal toxicity in patients treated with vaginal-cuff brachytherapy (VCB), with or without external beam radiotherapy (EBRT), and assess the impact of different prescription and optimization strategies on dose–volume parameters. Methods: We retrospectively analyzed 217 patients treated with EBRT combined with VCB (n = 120) or VCB alone (n = 97). In VCB three prescription and optimization strategies (volume-based, graphical optimization, and 5 mm distance-based prescription) were compared to determine differences in dose–volume parameters. In patients who developed late vaginal side effects, the dosimetric parameters were evaluated using descriptive statistics and Cox regression modeling. Kaplan–Meier analysis was performed to assess time to toxicity. Results: In the EBRT+VCB cohort, 34/120 patients (28.3%) developed grade 1–2 vaginal toxicity compared to 35/97 (36%) in the VCB alone cohort. In the EBRT+VCB group, patients with toxicity received a higher D90 per fraction and higher vaginal D2cc. In multivariable analysis, vaginal D2cc (HR = 1.60, 95% CI = 1.01–2.54, p = 0.045) and CTV-DVH (HR = 0.77, 95% CI = 0.61–0.97, p = 0.027) were independently associated with toxicity. No significant dose–toxicity associations were observed in the VCB-alone cohort. Most events occurred within 48 months in both groups. Comparison of prescription strategies showed systematic differences in target and organ-at-risk dose–volume parameters, including vaginal D2cc. The 5 mm distance-based prescription consistently resulted in higher D90, D100, EQD2, and vaginal D2cc values. Conclusions: In patients receiving EBRT combined with VCB, both vaginal D2cc and target dose distribution were associated with vaginal toxicity. The prescription and optimization strategy significantly influenced dose–volume parameters. Planning methodology and dosimetric aspects should be considered when interpreting dose–toxicity relationships in vaginal brachytherapy.